Carcinoma, Hepatocellular: Clinical Trials

3,390 trials for Carcinoma, Hepatocellular, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1181 completed, 824 unknown, 553 recruiting, 277 terminated. 1116 Phase 2, 654 Not applicable, 609 Phase 1, 317 Phase 3, 105 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21116Completed 353, Unknown 241, Recruiting 196, Terminated 127, Not yet recruiting 75, Withdrawn 63, Active not recruiting 56, Suspended 4, Enrolling by invitation 1
Not applicable654Completed 218, Unknown 184, Recruiting 101, Not yet recruiting 49, Terminated 46, Active not recruiting 25, Withdrawn 24, Enrolling by invitation 5, Suspended 2
Phase 1609Completed 231, Unknown 108, Recruiting 101, Terminated 80, Active not recruiting 37, Withdrawn 28, Not yet recruiting 19, Suspended 4, Enrolling by invitation 1
Phase 3317Completed 98, Unknown 98, Recruiting 37, Terminated 30, Active not recruiting 20, Not yet recruiting 15, Withdrawn 15, Suspended 3, Enrolling by invitation 1
Phase 4105Unknown 41, Completed 36, Recruiting 10, Not yet recruiting 8, Terminated 3, Withdrawn 3, Active not recruiting 2, Enrolling by invitation 2
Early Phase 153Completed 17, Unknown 13, Recruiting 7, Not yet recruiting 6, Terminated 6, Withdrawn 2, Active not recruiting 1, Suspended 1

Follow Carcinoma, Hepatocellular: new trials by email Literature Review of Carcinoma, Hepatocellular trials Research Report on Carcinoma, Hepatocellular

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Phase 2Not yet recruitingXiang-Qian1202027-09-012026-08-27
Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration
RayAblation - Liver Tumors
Not applicableNot yet recruitingM.D. Anderson Cancer Center2002027-04-012026-10-16
A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Ivonescimab - Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma
Phase 2Not yet recruitingMedSIR442027-03-012026-11-04
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Gardasil 9 vaccine, Hepatitis B Virus Vaccine(HBV), Cognitive Behavioral Therapy - Hepatitis B, Human Papilloma Virus
Phase 4Not yet recruitingEunice Dube21402027-01-302026-07-30
NK521 in the Treatment of Advanced Solid Tumors
NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer
Early Phase 1Not yet recruitingBase Therapeutics (Shanghai) Co., Ltd.182027-01-012026-09-30
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma
Phase 1Not yet recruitingAccSalus Biosciences, Inc.402027-01-012026-10-28
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
TheraSphere - Hepatocellular Carcinoma (HCC)
Not yet recruitingBoston Scientific Corporation1402027-01-012026-10-30
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention - Hepatocellular Carcinoma, Pancreas Cancer
Not applicableNot yet recruitingCity of Hope Medical Center702027-01-012026-11-10
A Single-Arm, Exploratory, Phase II Study of Iparomlimab and Tuvonralimab Combined With Local Therapy as First-Line Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
QL1706 (Iparomlimab/Tuvonralimab) - Hepatecellular Carcinoma
Phase 2Not yet recruitingFujian Cancer Hospital432027-01-012026-11-16
Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin
Parenchymal Blood Volume (PBV) Imaging, Nitroglycerin, Medical Record Review - Hepatocellular Carcinoma (HCC), Liver Cancer, Adult
Phase 2Not yet recruitingUniversity of California, San Francisco502026-12-152026-10-13
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) - Hepatocellular Carcinoma (HCC)
Phase 3Not yet recruitingUniversity Health Network, Toronto602026-12-012026-10-26
Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
Zanzalintinib, Tegavivint - Hepatocellular Carcinoma (HCC)
Phase 1 / Phase 2Not yet recruitingUniversity of Texas Southwestern Medical Center362026-12-012026-10-16
Erlotinib for Hepatocellular Carcinoma Chemoprevention
erlotinib hydrochloride, Placebo - Cirrhosis, Liver, Advanced Liver Fibrosis
Phase 2Not yet recruitingUniversity of Texas Southwestern Medical Center602026-12-012026-06-24
Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
Curative-Intent Liver Resection, Immunotherapy-Based Systemic Maintenance Therapy - Hepatocellular Carcinoma
Not applicableNot yet recruitingWest China Hospital602026-12-012026-10-08
QL1706 and Lenvatinib Combined With FOLFOX Systemic Chemotherapy as Second-line Treatment in Advanced Hepatocellular Carcinoma Patients
Intervention 1 - Drug QL1706 (Iparomlimab and Tuvonralimab) Intervention 2 - Drug Lenvatinib Intervention 3 - Drug FOLFOX Chemotherapy (Oxaliplatin, Fluorouracil, and Levoleucovorin Calcium) - Hepatocellular Carcinoma (HCC)
Phase 2Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University332026-12-012026-11-12
90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Not yet recruitingBeijing Tsinghua Chang Gung Hospital2002026-12-012026-11-17
PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC
Lenvatinib, Partial transarterial chemoembolization (TACE) - Hepatocellular Carcinoma
Phase 2Not yet recruitingChang Gung Memorial Hospital402026-11-302026-11-03
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
BGB-B2033 - Hepatocellular Cancer, Liver Cancer
Phase 2Not yet recruitingBeOne Medicines1002026-11-302026-11-03
Risk Factors and Early Predictors of Bile Leak After Major Liver Resection
Major hepatectomy, Drain-fluid and serum bilirubin measurement - Bile Leak, Biliary Fistula
Not yet recruitingMinia University1002026-11-252026-11-19
Assessment of Patient Radiation Exposure and Development of Diagnostic Reference Levels(DRLs) Standards for Endoscopic Retrograde Cholangiopancreatography (ERCP).
Choledocholithiasis, Biliary Stricture
Not yet recruitingInstitute of Liver and Biliary Sciences, India1502026-11-162026-11-18

Showing 20 of 3390. Sign in to see all of them.

Narrower conditions

Liver Neoplasms (530)  ·  Stomach Neoplasms (153)  ·  Neoplasms (149)  ·  Carcinoma, Non-Small-Cell Lung (141)  ·  Colorectal Neoplasms (137)  ·  Carcinoma, Renal Cell (135)  ·  Pancreatic Neoplasms (129)  ·  Cholangiocarcinoma (116)  ·  Melanoma (115)  ·  Liver Cirrhosis (97)  ·  Fibrosis (93)  ·  Neoplasm Metastasis (92)  ·  Esophageal Neoplasms (87)  ·  Breast Neoplasms (83)

Broader conditions

Neoplasms by Histologic Type (3383)  ·  Neoplasms by Site (3382)  ·  Adenocarcinoma (3380)  ·  Digestive System Diseases (3380)  ·  Neoplasms, Glandular and Epithelial (3380)  ·  Digestive System Neoplasms (3371)  ·  Carcinoma (3349)  ·  Liver Diseases (3337)  ·  Neoplasms (3241)  ·  Liver Neoplasms (2860)  ·  Pathological Conditions, Signs and Symptoms (486)  ·  Pathologic Processes (444)  ·  Gastrointestinal Diseases (284)  ·  Gastrointestinal Neoplasms (258)  ·  Urogenital Diseases (247)

Interventions

Sorafenib (224)  ·  lenvatinib (154)  ·  Bevacizumab (141)  ·  Nivolumab (91)  ·  atezolizumab (84)  ·  Radiosurgery (76)  ·  pembrolizumab (76)  ·  durvalumab (65)  ·  sintilimab (65)  ·  Oxaliplatin (61)  ·  Fluorouracil (57)  ·  tislelizumab (48)  ·  Doxorubicin (47)  ·  apatinib (46)  ·  Radiofrequency Ablation (44)

Sponsors

Sun Yat-sen University (169)  ·  National Cancer Institute (NCI) (75)  ·  Seoul National University Hospital (60)  ·  Shanghai Zhongshan Hospital (58)  ·  Eastern Hepatobiliary Surgery Hospital (46)  ·  Fudan University (44)  ·  National Taiwan University Hospital (40)  ·  Assistance Publique - Hôpitaux de Paris (39)  ·  M.D. Anderson Cancer Center (35)  ·  Guangxi Medical University (34)  ·  Bayer (33)  ·  Tianjin Medical University Cancer Institute and Hospital (30)  ·  Second Affiliated Hospital of Guangzhou Medical University (27)  ·  Zhejiang University (27)  ·  Zhongda Hospital (26)

Countries

China (1163)  ·  United States (896)  ·  South Korea (277)  ·  France (271)  ·  Taiwan (262)  ·  Italy (197)  ·  Spain (153)  ·  Germany (143)  ·  Canada (122)  ·  Hong Kong (115)  ·  Japan (110)  ·  United Kingdom (107)  ·  Singapore (88)  ·  Belgium (84)  ·  Australia (73)

Top investigators

Ming Shi, MD (21)  ·  Jeong Min Lee, MD (14)  ·  Tim F Greten, M.D. (11)  ·  David Hsieh, MD (7)  ·  Gao-Jun Teng, M.D. (6)

Results publications

PMID 12049862, PMID 11981766, PMID 12540794, PMID 18650514, PMID 19192962, PMID 19095497, PMID 29628281, PMID 32402160, PMID 34143971, PMID 36852452, PMID 12091661, PMID 21374666, PMID 27932229, PMID 29433850, PMID 29471013, PMID 29875066, PMID 32557715, PMID 32716739, PMID 33538338, PMID 34905388, PMID 14667750, PMID 19766639, PMID 26361969, PMID 30207593, PMID 31070690, PMID 31401903, PMID 35421228, PMID 36529152, PMID 38319892, PMID 39437804, PMID 10207464, PMID 14762851, PMID 16250051, PMID 16495695, PMID 16557381, PMID 16908937, PMID 18477802, PMID 19212170, PMID 19908093, PMID 19949018, PMID 20175033, PMID 20203173, PMID 20590903, PMID 20839057, PMID 22002018, PMID 22424438, PMID 22968066, PMID 23099728, PMID 23269991, PMID 23393196

NIH funding

2023 (16), 2016 (11), 2017 (10), 2018 (10), 2019 (10), P30CA016672 (10), P30CA060553 (9), 2025 (8), P30CA015083 (8), 2009 (7), 2014 (7), P30CA014089 (7), P30CA033572 (7), 2015 (6), N01CM62201 (5)